Related Experiment Videos
Getting to goal in complex patients
1Texas Blood Pressure Institute, Dallas Nephrology Associates, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA. ramv@dneph.com
Insights
Complex hypertension management requires expanded definitions to include silent organ damage and high-risk groups. Aggressive blood pressure (BP) lowering, particularly with combination therapy, is crucial for halting vascular disease progression.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Complex hypertension traditionally defined by overt target organ damage.
- Expanded definition includes patients with silent organ damage or high risk of developing it.
- Significant number of hypertensive patients require specialized management.
Purpose of the Study:
- To broaden the understanding of complex hypertension beyond manifest disease.
- To highlight factors contributing to complex hypertension classification.
- To emphasize the importance of aggressive blood pressure control and effective therapeutic strategies.
Main Methods:
- Review of existing literature and clinical trial evidence.
- Identification of factors defining complex hypertension (e.g., severe hypertension, comorbidities, high-risk populations).
- Evaluation of therapeutic approaches focusing on goal blood pressure achievement.
Main Results:
- Complex hypertension encompasses patients with silent organ damage and high-risk demographics (elderly, African Americans).
- Severe hypertension, diabetes, renal insufficiency, coronary artery disease, and heart failure are key classifying factors.
- Aggressive blood pressure lowering is essential for halting vascular disease progression.
Conclusions:
- Combination therapy, specifically calcium-channel blockers and angiotensin-converting enzyme inhibitors, demonstrates efficacy and organ protection in complex hypertension.
- Achieving goal blood pressure is paramount, with drug selection prioritizing efficacy, organ protection, and tolerability.
- Evidence supports favorable outcomes with combined therapies in managing complex hypertension.
Abstract:
Traditionally, the term complex hypertension has been applied to patients who have clinical evidence of target organ damage. However, this definition can be expanded to include many hypertensive patients who either present without manifest disease but harbor silent concomitant organ damage, or belong to a high-risk group and are likely to develop such damage. Thus, the number of patients who deserve special consideration as complex patients is considerable. Various factors may contribute toward classifying a patient as having complex hypertension. These include severe hypertension, concomitant conditions such as diabetes, chronic renal insufficiency, coronary artery disease, orcongestive heart failure; and high-risk populations such as the elderly and African Americans. Recent evidence demonstrates that aggressive goal blood pressure (BP)-lowering therapy is the key toward halting the progression of vascular disease. Although the choice of initial therapy seems less important than achieving goal BP, the drug selected must impart efficacy, organ protection, and tolerability. Combination therapy consisting of calcium-channel blockers and angiotensin-converting enzyme inhibitors seems to achieve these desirable effects. Several clinical trials have demonstrated these agents to have favorable effects on BP and organ protection even in complex hypertension, particularly when used in combination.